Related Experiment Videos
Bruising associated with sibutramine: results from postmarketing surveillance in New Zealand
M Harrison-Woolrych1, G R Hill, D W J Clark
1Intensive Medicines Monitoring Programme, Department of Preventive and Social Medicine, University of Otago, Dunedin, New Zealand. Mira.harrison-woolrych@stonebow.otago.ac.nz
Objective:
To determine whether postmarketing data provide evidence of an association of sibutramine with bruising.
Design And Patients:
During a postmarketing surveillance study of sibutramine in New Zealand by the Intensive Medicines Monitoring Programme (IMMP), a series of reports of bruising was identified. Further case reports were also obtained from the World Health Organisation (WHO) adverse drug reactions database.
Outcome Measures:
All platelet, bleeding and clotting events associated with sibutramine were identified and causality assessments were performed.
Results:
From the IMMP and WHO databases a total of 16 cases of bruising that improved on withdrawal of sibutramine were identified. Of these, two had a recurrence of bruising on reintroduction of sibutramine.
Conclusions:
Evidence from postmarketing surveillance suggests that there is a causal association between sibutramine and bruising/ecchymosis. This represents a newly recognized adverse reaction for this medicine.
Related Concept Videos
Pharmacovigilance
This process, termed pharmacovigilance, aims to detect, evaluate, and minimize harmful effects related to medication use. The data collection for pharmacovigilance depends on spontaneous reporting systems, where healthcare professionals or patients voluntarily report suspected ADRs.
In some cases, there...
Drugs for Treatment of Constipation-Predominant IBS
Drug Toxicity: Risk factors
Therapeutic Drug Monitoring: Affecting Factors
Acute Coronary Syndrome III: Diagnostic Studies
Drugs for Treatment of Diarrhea-Predominant IBS
Two specific drugs used in the treatment are alosetron (Lotronex) and eluxadoline (Viberzi). Alosetron, a 5-HT3 antagonist, works by slowing the movement of stools in the gut, reducing bowel...